A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01)

• Type of Material: Poster
• Authors: Joseph Clark, Loyola University; Lawrence Flaherty, Karmanos Cancer Center; Marc Ernstoff, Dartmouth University; Henry Koon, CWRU University Hospitals; Mohammed Milhem, University of Iowa; Gerald Militello, Hematology/Oncology Clinic; Sanjiv Agarwala, Saint Luke's Cancer Center; Brendan Curti, Earle A. Chiles Research Institute; Lee Cranmer, University of Arizona Cancer Center; Christopher D. Lao, University of Michigan; Theodore F. Logan, Indiana University; Jose Lutzky, University of Miami Medical Center; Venkatesh Rudrapatna, University of Minnesota; Gregory Daniels, Moores Cancer Center; Bret Taback, Columbia University; Sandra Aung, Prometheus Laboratories; James Lowder, Prometheus Laboratories; David Lawson, Emory University
• Language: English
• Date: 2014-11-06
• Publisher: Emory University Libraries
• Copyright Statement: © 2014 Clark et al.; licensee BioMed Central Ltd.
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): https://jitc.biomedcentral.com/articles/10.1186/2051-1426-2-S3-P77
• Conference or Event Name: Society for Immunotherapy of Cancer 29th Annual Meeting National Harbor, MD, USA.
• Research Categories: Health Sciences, General; Health Sciences, Medicine and Surgery